Difference between revisions of "Envoplakin"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 44: | Line 44: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Epidermal transglutaminase|*]] | [[Category:Epidermal transglutaminase|*]] | ||
Latest revision as of 11:09, 10 March 2015
| Envoplakin | |
|---|---|
| Substrate peptide name | Envoplakin |
| Synonyms | - |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cornified envelope |
| Swissprot ID | Q92817 |
| Reactive glutamines | Q1970, Q1973 |
| Reactive lysines | Not determined yet |
| Substrate sequence | SEELAQLLQDESSF |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:9482839 |
| Notes | |
